EFNS 2012
About EFNS
Grants and Awards
General Information
Registration
Scientific Programme and Call for Abstracts
Additional Events
Sponsorship and Exhibition
Travel and Accommodation

Webcasting – Recorded sessions 

Freely accessible sessions

Targeting synapse loss – Clinical evidence for a new approach in early Alzheimer's disease

Chair introduction
Strategies for managing early AD
Hilkka Soininen, Finland

Management of AD: Where do we stand?
Ian McKeith, UK

Introducing a new concept in AD, targeting synapse loss
Patrick Kamphuis, the Netherlands

The Souvenaid clinical trial programme: What have we learnt?
Christine von Arnim, Germany

A satellite symposium sponsored by Nutricia


Short Communications session 3: Ageing and Dementia
A randomized, double-blind, placebocontrolled clinical trial of intravenous bapineuzumab in patients with Alzheimer's disease who are apolipoprotein E ε4 carriers
Speaker: Reisa Sperling
Sperling_Bapineuzumab IV Study 302_EFNS Presentation Slides_9-11-2012.pdf

A randomized, double-blind, placebocontrolled clinical trial of intravenous bapineuzumab in patients with Alzheimer's disease who are apolipoprotein E ε4 non-carriers
Speaker: Steven Salloway
Salloway_Bapineuzumab IV Study 301_EFNS Presentation Slides_9-11-2012.pdf

Production of the webcast was funded by the Alzheimer’s Immunotherapy Program of Janssen Alzheimer Immunotherapy and Pfizer Inc.


All EFNS 2012 webcasts are now freely available through: http://webcasts.kenes.com/efns/WebcastAll.aspx